Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

被引：0
|
作者：
Yoshihide Ueda
Toru Ikegami
Nobuhisa Akamatsu
Akihiko Soyama
Masahiro Shinoda
Ryoichi Goto
Hideaki Okajima
Tomoharu Yoshizumi
Akinobu Taketomi
Yuko Kitagawa
Susumu Eguchi
Norihiro Kokudo
Shinji Uemoto
Yoshihiko Maehara
机构：
[1] Kyoto University,Department of Gastroenterology and Hepatology, Graduate School of Medicine
[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[3] University of Tokyo,Division of Artificial Organ and Transplantation, Department of Surgery
[4] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery
[5] Keio University School of Medicine,Department of Surgery
[6] Hokkaido University Graduate School of Medicine,Department of Gastroenterological Surgery I
[7] Kyoto University,Department of Surgery, Graduate School of Medicine
来源：
Journal of Gastroenterology | 2017年 / 52卷
关键词：
Hepatitis C; Liver transplantation; Living donor; Sofosbuvir; Ledipasvir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：986 / 991
页数：5
相关论文
共 50 条
  • [21] Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
    Lim, Joseph K.
    Liapakis, Ann Marie
    Shiffman, Mitchell L.
    Lok, Anna S.
    Zeuzem, Stefan
    Terrault, Norah A.
    Park, James S.
    Landis, Charles S.
    Hassan, Mohamed
    Gallant, Joel
    Kuo, Alexander
    Pockros, Paul J.
    Vainorius, Monika
    Akushevich, Lucy
    Michael, Larry
    Fried, Michael W.
    Nelson, David R.
    Ben-Ari, Ziv
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (11) : 1811 - +
  • [22] Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study
    Charlton, Michael R.
    Gane, Edward J.
    Manns, Michael P.
    Brown, Robert S.
    Curry, Michael P.
    Kwo, Paul Y.
    Fontana, Robert J.
    Gilroy, Richard
    Teperman, Lewis W.
    Muir, Andrew J.
    McHutchison, John G.
    Symonds, William T.
    Denning, Jill M.
    McNair, Lindsay
    Arterburn, Sarah
    Terrault, Norah
    Samuel, Didier
    Forns, Xavier
    HEPATOLOGY, 2013, 58 (06) : 1378A - 1378A
  • [23] SAFETY AND TOLERABILITY OF RECURRENT HEPATITIS C TREATMENT IN POST LIVER AND LIVER/KIDNEY TRANSPLANT PATIENTS TREATED WITH LEDIPASVIR/SOFOSBUVIR WITH AND WITHOUT RIBAVIRIN OR SOFOSBUVIR WITH RIBAVIRIN: SINGLE CENTER EXPERIENCE
    Selim, K.
    Elhazin, B.
    Long, W.
    Karmanova, M.
    Salazar, J.
    Volk, M.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S788 - S789
  • [24] Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation
    Pungpapong, Surakit
    Werner, K. Tuesday
    Aqel, Bashar
    Leise, Michael D.
    Murphy, Jennifer L.
    Henry, Tanisha M.
    Ryland, Kristen
    Chervenak, Amy E.
    Watt, Kymberly D.
    Vargas, Hugo E.
    Keaveny, Andrew
    HEPATOLOGY, 2014, 60 : 201A - 201A
  • [25] Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin
    Götz, G
    Schön, MR
    Haefker, A
    Neuhaus, R
    Berg, T
    Hopf, U
    Neuhaus, P
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) : 2104 - 2106
  • [26] Multicenter Preliminary Experience Utilizing Boceprevir with Pegylated Interferon and Ribavirin for Treatment of Recurrent Hepatitis C Genotype 1 after Liver Transplantation
    Aqel, Bashar
    Koning, Ludi
    Charlton, Michael
    Carey, Elizabeth J.
    Byrne, Thomas J.
    Rakela, Jorge
    Vargas, Hugo E.
    HEPATOLOGY, 2012, 56 : 530A - 530A
  • [27] Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection
    Colombo, Massimo
    Aghemo, Alessio
    Liu, Hong
    Zhang, Jie
    Dvory-Sobol, Hadas
    Hyland, Robert
    Yun, Chohee
    Massetto, Benedetta
    Brainard, Diana M.
    McHutchison, John G.
    Bourliere, Marc
    Peck-Radosavljevic, Markus
    Manns, Michael
    Pol, Stanislas
    ANNALS OF INTERNAL MEDICINE, 2017, 166 (02) : 109 - +
  • [28] Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation
    Aly, Osama Aboelfotoh
    Yousry, Wael Ahmed
    Teama, Nahla Mohamed
    Shona, Eman Mohammed
    ElGhandour, Ahmed Mohamed
    EGYPTIAN LIVER JOURNAL, 2020, 10 (01)
  • [29] Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation
    Osama Aboelfotoh Aly
    Wael Ahmed Yousry
    Nahla Mohamed Teama
    Eman Mohammed Shona
    Ahmed Mohamed ElGhandour
    Egyptian Liver Journal, 10 (1)
  • [30] Sofosbuvir, Velpatasvir , and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
    Cardona-Gonzalez, Maria G.
    Goldman, Jason D.
    Naravan, Lawrence
    Brainard, Diana M.
    Kowdley, Kris, V
    HEPATOLOGY COMMUNICATIONS, 2018, 2 (12) : 1446 - 1450
12345